Cargando…
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression
Histone deacetylase inhibitors (HDIs) represent a new class of anticancer drugs. Suberoylanilide hydroxamic acid (SAHA), the first HDI approved for the treatment of cutaneous T cell lymphoma (CTCL), is currently being tested in clinical trials for other cancers. However, SAHA has been ineffective ag...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891104/ https://www.ncbi.nlm.nih.gov/pubmed/26848526 http://dx.doi.org/10.18632/oncotarget.7134 |